Infectious Disease

A recent study reveals diverse long COVID trajectories, highlighting the need for further research to understand symptoms and recovery variability.

Measles resurges globally, threatening U.S. elimination status; pharmacists play a crucial role in vaccination efforts and outbreak response.

Amoxicillin is a favorable choice for outpatient use in pediatric patients given its relatively narrow spectrum of activity and palatable formulation.

The SmartPhrase listed indications for PCV20 aligned with CDC guidelines and was incorporated into provider documentation, significantly improving vaccine uptake.

Epstein-Barr virus may trigger lupus, reshaping our understanding of this complex autoimmune disease.

The CLEAR framework helps guide pharmacists during the process of assessing and delabeling β-lactam allergies to improve patient outcomes.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

A series of predictors were associated with a higher likelihood of intensive care unit (ICU) admission and subsequently poor outcomes in patients with Streptococcus pneumoniae bacteremia.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

Adults in the United States are often infected by serotypes of Streptococcus pneumoniae unique to the pneumococcal 21-valent conjugate vaccine (PCV21) compared with those unique to PCV20.

Multiplex respiratory virus testing enhances clinical decision-making for RSV in community hospitals.

In children and adolescents, reinfection with COVID-19 increased the risk of worsened long COVID outcomes.

A groundbreaking vaccine shows 73% efficacy against Salmonella Paratyphi A, offering hope in combating enteric fever globally.

Although the incidence of vascular assess-associated infections (VAIs) was low, the incidence caused by noncuffed catheters (NCC) was high.

Low RSV vaccination rates among older adults in the US highlight missed opportunities for reducing hospitalizations and health care costs.

The 20-valent pneumococcal conjugate vaccine (PCV20) demonstrated higher vaccine effectiveness against invasive pneumococcal disease or all-cause pneumonia in cohorts of older adults.

Influenza vaccination provided direct, non–infection-based benefits in older adults.

New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Increasing vaccine confidence demands that pharmacists move beyond simply sharing facts to utilizing effective communication strategies.

Pharmacists play a vital role in managing respiratory virus season by providing vaccinations, counseling, and recommending effective treatments for patients.